Life sciences partner Katherine Wang (Shanghai) is quoted in a March 21 article in The Pink Sheet regarding a China Food and Drug Administration (CFDA) draft regulation that proposes to revise a burdensome requirement relating to the conduct of multi-regional clinical trials (MRCTs) at sites in China, and which will potentially allow simultaneous conduct of early-stage studies in the country.
Ms. Wang notes that the CFDA proposed rule changes would have the positive effects of both helping to obtain clinical trial approvals and easing requirements on new drug applications for imported drugs in China.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.